Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MMJ-002
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
DEA Continues to Block MMJ Marijuana Drug Development for Neurological Disorder
Details : MMJ-002 is a novel cannabis-derived medication, being investigated for the treatment of chorea associated with Huntington's disease (HD).
Product Name : MMJ-002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : MMJ-002
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable